Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field.
Lumley SF. et al, (2025), Lancet Microbe
A putative hepatitis B virus sequence motif associated with hepatocellular carcinoma in South African adults.
Maponga TG. et al, (2025), Ann Hepatol, 30
Whole genome sequencing of hepatitis B virus using tiled amplicon (HEPTILE) and probe based enrichment on Illumina and Nanopore platforms.
Lumley SF. et al, (2025), Sci Rep, 15
Is health, growth and development impaired in children who are Hepatitis B-exposed but uninfected?
Lumley SF. et al, (2025), PLOS Glob Public Health, 5
A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir.
Lumley SF. et al, (2024), J Clin Virol, 174
Peer support for people living with hepatitis B virus-A foundation for treatment expansion.
Downs LO. et al, (2024), J Viral Hepat, 31, 490 - 499
Multiple risk factors for persistent HBV viraemia in an adult receiving nucleos/tide analogue therapy.
Lumley S. et al, (2024), Sex Transm Infect, 100, 329 - 331
Social, clinical and biological barriers to hepatitis B virus suppression with nucleos/tide analogue therapy: who is at risk and what should we do about it?
Im YR. et al, (2024), Sex Transm Infect, 100, 259 - 263
Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection.
Delphin M. et al, (2024), Lancet Gastroenterol Hepatol, 9, 383 - 392